JAK1

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, JAK1, American Academy, LSM, Patient, AAD, Week, Safety, American Academy of Dermatology, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
  • Results from the study demonstrate that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index (T-VASI) scores.
  • “Vitiligo is a chronic, immune-mediated disease which, until recently, had limited treatment options available to patients.
  • “As vitiligo can impact patients in different ways, I am encouraged by the continued focus on expanding medical treatment options, and I believe these data highlight the potential of this investigational oral treatment for patients with extensive nonsegmental vitiligo.”

Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 6, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Cream, Shift, Janus, American Academy, Chronic, Journal, Dermatology, Conference call, Patient, Interest, Hidradenitis suppurativa, American Academy of Dermatology, AAD, Janus kinase inhibitor, Inflammation, JAK1, Use, Adolescence, Atopic dermatitis, Randomness, Post hoc analysis, Autoimmunity, Maintenance, JAAD, Conference, Abstract, HS, Safety, Cryptocurrency, Pharmaceutical industry, Communications satellite, Disease, Vitiligo, Incyte

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans.
  • “The research being featured at this year’s AAD Annual Meeting highlights the potential of Incyte therapies to meet the needs of patients living with vitiligo and other serious skin conditions,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Saturday, March 18, 9:30 a.m. CT)
    Efficacy and Safety of Povorcitinib in Vitiligo: Results from a Phase 2, Placebo-Controlled, Dose Ranging Study (Session: S042 – Late-Breaking Research: Session 2.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2023.

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 28, 2023
Janus, Skin, Hair, SG, Psoriasis, ESG, Research, Vitiligo, Acquisition, JAK1, Webcast, FDA, Patient, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biophysical environment, Scalp, NDA, Growth, Inflammation, PDE4, Prescription, New Drug Application, Shanda, Pharmacy, Alopecia areata, Food, Ageing, Dermatitis, Atopic dermatitis, Video game, Health insurance, Pharmaceutical industry, Cosmetics, Cryptocurrency

In the fourth quarter of 2022, Arcutis announced positive topline results from INTEGUMENT-1 and INTEGUMENT-2, the two pivotal Phase 3 trials evaluating roflumilast cream 0.15% for the treatment of atopic dermatitis in individuals 6 years of age or older.

Key Points: 
  • In the fourth quarter of 2022, Arcutis announced positive topline results from INTEGUMENT-1 and INTEGUMENT-2, the two pivotal Phase 3 trials evaluating roflumilast cream 0.15% for the treatment of atopic dermatitis in individuals 6 years of age or older.
  • In September 2022, Arcutis announced positive topline results from the ARRECTOR pivotal Phase 3 trial for the treatment of scalp and body psoriasis.
  • Net cash used in operating activities was $71.1 during the fourth quarter and $257.7 million during the full year 2022.
  • Arcutis management will host a conference call and webcast today at 4:30pm ET to discuss the financial results for the quarter and provide a business update.

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Retrieved on: 
Monday, February 27, 2023
JAK, Safety, Cate, Doctor of Philosophy, Hugo, FRCPC, Filgotinib, CET, JAK1, Research, Anemia, Patient, LTE, Abstract, Quality of life (healthcare), Ulcerative colitis, RA, Rheumatoid arthritis, ECCO, European, Congress, Western University, Epidemiology, IBD, Galapagos NV, Euronext, Pharmaceutical industry, Biostatistics, MD, UC, Galápagos Islands, Immunology

A number of abstracts will present analyses from the SELECTION program with filgotinib.

Key Points: 
  • A number of abstracts will present analyses from the SELECTION program with filgotinib.
  • Additionally, Galapagos will present pooled data from five Phase 2/3 trials, and two long-term extension trials of filgotinib designed to further understand the safety profile of filgotinib in UC and rheumatoid arthritis (RA).
  • “We are excited to present data from multiple studies of filgotinib in UC, including results from the SELECTIONLTE study, which has been selected amongst the top 11 oral abstracts at ECCO,” said Daniele D’Ambrosio, MD, PhD, Therapeutic Area Head, of Immunology, at Galapagos.
  • Amongst subjects who completed the study, the reduction in mean pMCS in SELECTION was maintained up to LTE Week 144.

ASN002 (Gusacitinib) Emerging Drug Insight and Market 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 23, 2023
Health, Pharmaceutical, Janus, Clinical trial, HE, JAK, JAK3, News, SYK, B cell, JAK1, Research, United Kingdom, EU4, T helper 17 cell, Keratinocyte, CHE, T helper cell, Neutrophil, Book, Pancreatic serous cystadenoma, Macrophage, JAK2, TYK2, Cytokine, Lymphoma, Epithelium, SWOT, Fine chemical, Pharmaceutical industry, Vaccine, Hand eczema

The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Further, it also consists of future market assessments inclusive of the ASN002 (Gusacitinib) market forecast, analysis for Hand Eczema in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hand Eczema.
  • Other emerging products for Hand Eczema (HE) are expected to give tough market competition to ASN002 (Gusacitinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What is the clinical trial status of the study related to ASN002 (Gusacitinib) in Hand Eczema (HE) and study completion date?

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Retrieved on: 
Friday, February 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, South African Class MG 2-6-6-2, CK, Inflammation, Acne, Drug development, Abstract, Week, Upper respiratory tract infection, Safety, Patient, Common, Urinary tract infection, Associate, Hidradenitis suppurativa, JAK1, Autoimmunity, Conference, COVID-19, HS, Headache, Pharmaceutical industry, Abscess

Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS).
  • These data were presented as an oral presentation (Abstract #258) at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held from February 8-10, 2023, in Florence, Italy.
  • Povorcitinib was generally well tolerated and the safety profile was consistent with previously-reported data.
  • We look forward to continuing to progress the development of povorcitinib through our ongoing Phase 3 trial in patients with moderate-to-severe HS.”
    Additional 52-week efficacy results include:

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

Retrieved on: 
Wednesday, February 8, 2023
CET, Cohort study, Galapagos NV, Disease, RA, JAK1, Safety, MD, Filgotinib, Axial spondyloarthritis, Euronext, UZ Leuven, UC1, University of Leuven, University, Patient, UC, Crohn's disease, Week, Maintenance, Marketing, Research, Doctor of Philosophy, Pharmaceutical industry, Immunology, Galápagos Islands, Cohort

Induction Cohort A included biologic-naïve (54%) and biologic-experienced (46%) patients; induction Cohort B included biologic-experienced patients.

Key Points: 
  • Induction Cohort A included biologic-naïve (54%) and biologic-experienced (46%) patients; induction Cohort B included biologic-experienced patients.
  • In total, 33% of patients in Cohort A and 52% of patients in Cohort B had failed treatment with 3 or more biologic drugs.
  • Both induction cohorts of the study failed to meet the co-primary endpoints of clinical remission and endoscopic response for filgotinib, 100mg and 200mg once daily.
  • We are grateful to the patients and all medical professionals who participated in this trial.”

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Janus, Disease, Sun Pharma, BSE, NSE, Autoimmune disease, R, CNCE, JAK1, CVR, Depression, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Safety, Deuterium, FDA, Hair loss, NDA, Woman, Immune system, Scalp, Food, Patient, CVR Partners, JAK2, Sale, Acquisition, Multimedia, Janus kinase, Reuters, Alopecia areata, Life, Investment, Concert, Hair, Wardwell, Security (finance), Pharmaceutical industry, Ophthalmology

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.

Key Points: 
  • Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime1,2,3.
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma.
  • “There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community.